The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

The researchers revealed that GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...